QDEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
QDEL is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical strength, but the overall setup is still weakened by bearish analyst revisions, weak recent operating commentary, and no clear bullish catalyst. Since the user is impatient and not waiting for a better entry, I still would not buy here; the better call is to hold off until the trend and fundamentals improve.
Technically, QDEL is mixed to slightly bullish in the very short term. The MACD histogram is positive and expanding, which supports near-term momentum. However, RSI_6 at 72.169 suggests the stock is already stretched and near overbought levels rather than offering an attractive entry. Moving averages are converging, which usually signals an indecisive trend rather than a strong sustained uptrend. Price is trading around 13.01-13.07, just below resistance at R1 13.125 and far above support at 11.878, so upside may be limited unless it can break resistance convincingly. The short-term pattern forecast is modestly positive, but not strong enough to override the broader caution.
["MACD histogram is positive and expanding, supporting near-term momentum", "Insiders are buying, with buying amount up 2578.44% over the last month", "No negative news was reported in the last week", "Short-term pattern analysis suggests modest upside over the next week and month"]
["Multiple analyst price target cuts in early May signal weakening Wall Street confidence", "Jefferies downgraded the stock from Buy to Hold and cut the target sharply to 12.50 from 35", "JPMorgan cut its target to 11 and cited weak respiratory results and China policy headwinds", "UBS and Citi also lowered targets, showing a broad reset in expectations", "Options positioning is put-heavy, indicating cautious sentiment", "RSI is elevated, which makes the current price less attractive for immediate new buying", "No recent news catalyst to drive a fresh re-rating upward"]
Latest quarter financials were not provided due to a snapshot error, so there is no usable quarterly revenue or earnings detail to analyze. Based on the analyst commentary, however, the latest quarter appears to have disappointed, especially in respiratory performance, and the 2026 outlook depends on a second-half inflection across several regions. That implies growth visibility is still uncertain rather than clearly improving.
Wall Street sentiment has turned cautious to negative. UBS, Citi, JPMorgan, and Jefferies all lowered price targets in May 2026, and Jefferies downgraded the stock to Hold from Buy. Current targets cluster around $11-$13, which is close to the current price around $13, suggesting limited near-term upside. The pros view is that the stock may have some recovery potential if second-half improvements materialize and insiders are indeed accumulating. The cons view is stronger: recent results were disappointing, respiratory weakness persists, China policy risk remains, and deleveraging is increasingly uncertain. Overall, analysts are mostly neutral to bearish.
